Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred StockCRANFORD, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has extended the expiration date for the exchange offer by the Company to each holder of its Series C Non-Convertible Redeemable Preferred Stock, $0.01 par value per share (the “Series C Preferred Stock”), to exchange such Series C Preferred Stock for shares of Enzon’s common stock, $0.01 par value per share (the “Common Stock”). After giving effect to the extension, the offer expires one minute after 11:59 p.m., Eastern Time, on March 9, 2026, unless the offer is further extended.
Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase MergerCRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”), today announced that it has commenced an exchange offer (the “Offer”) involving its Series C Non-Convertible Redeemable Preferred Stock (the “Series C Preferred Stock”) identified in the Prospectus/Consent Solicitation/Offer to Exchange (as defined below) in connection with Enzon’s previously announced merger with Viskase Companies, Inc. (“Viskase”).
Enzon and Viskase Announce Amendment to Merger AgreementEnzon and Viskase stockholders will respectively own 45% and 55% of the combined company
Enzon and Viskase Enter into Merger AgreementEnzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined company
